

Special Issue

Novel Biomarkers for Acute and Chronic Heart Failure

Message from the Guest Editors

Heart failure is acknowledged as a major and growing public health problem. It is currently a devastating syndrome with a very negative impact on mortality, morbidity, and health-related quality of life. Heart failure is also considered an international priority in healthcare due to its growing prevalence and to the rising medical resource use and expenditure. The use of biomarkers in the management of patients with heart failure has increased over the past few years. Biomarkers contribute to making reliable tools for a systematic and optimized strategy in heart failure diagnosis and treatment. Recent advances in research have settled the basis for biomarker testing and diagnostic evaluation in heart failure; however, there are still many gaps of knowledge regarding the use of biomarkers for patient-centered integrated early diagnosis and risk stratification. This Special Issue will provide novel findings and innovations in the field of biomarkers, to ensure more efficiency for heart failure condition through multidisciplinary and integrated management approach.

Guest Editors

Dr. Josep Comín-Colet

1. Cardiology Department, Heart Institute, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
2. Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
3. Community Heart Failure Program, Cardiology Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
4. Centro de Investigación Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto Salud Carlos III, 28029 Madrid, Spain
5. Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain

Dr. Cristina Enjuanes-Grau

Hospital Universitari de Bellvitge, Barcelona, Spain

Deadline for manuscript submissions

closed (10 July 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/99164

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://mdpi.com/journal/)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).